Table 4.
Any recurrence | Lung cancer-specific death | |||
---|---|---|---|---|
Cohort, Variable | SHR (95% CI) | p | SHR (95% CI) | p |
MODEL 1 Overall (n=188) | ||||
Histologic subtype (vs LCNEC) | ||||
AC | 0.81 (0.45, 1.46) | 0.480 | 0.55 (0.27, 1.11) | 0.094 |
SCLC | 0.47 (0.23, 0.98) | 0.019 | 0.59 (0.32, 1.11) | 0.1 |
Sex: male (vs. female) | 2.05 (1.24, 3.38) | 0.005 | 1.96 (1.09, 3.53) | 0.024 |
Smoking pack-years (per 1 pack/year increase) | — | — | 1.01 (1.00, 1.01) | 0.003 |
Adjuvant therapy (vs no adjuvant) | 1.72 (0.96, 3.08) | 0.068 | 1.29 (0.69, 2.42) | 0.4 |
Lymphatic invasion (vs absent) | 2.21 (1.20, 4.09) | 0.011 | 2.85 (1.36, 5.98) | 0.005 |
STAS (present vs absent) | 2.85 (1.73, 4.68) | <0.001 | 2.72 (1.57, 4.70) | <0.001 |
MODEL 2: LCNEC (n=93) | ||||
Sex: male (vs. female) | 2.13 (1.10, 4.12) | 0.026 | 2.20 (1.10, 4.40) | 0.025 |
Adjuvant therapy (vs no adjuvant) | 1.51 (0.69, 3.3) | 0.3 | 0.91 (0.45, 1.86) | 0.8 |
Lymphatic invasion (vs absent) | 2.49 (1.18, 5.27) | 0.017 | 3.17 (1.38, 7.28) | 0.006 |
STAS (present vs absent) | 2.39 (1.26, 4.54) | 0.008 | 2.42 (1.21, 4.84) | 0.012 |
MODEL 3: SCLC (n=57) | ||||
Smoking pack-years (per 1 pack/year increase) | 1.02 (1.00, 1.04) | 0.017 | — | — |
Adjuvant therapy (vs no adjuvant) | 6.61 (1.68, 25.92) | 0.007 | — | — |
Lymphatic invasion (vs absent) | 4.14 (0.82, 20.87) | 0.086 | — | — |
Pleural invasion (vs absent) | — | — | 3.67 (1.19, 11.34) | 0.024 |
Necrosis percentage (per 1% increase) | 1.03 (1.01, 1.05) | 0.007 | 1.04 (1.01, 1.07) | 0.003 |
STAS (present vs absent) | 2.63 (0.86, 8.03) | 0.090 | 4.06 (1.33, 12.35) | 0.014 |
Significant p values are shown in bold. AC, atypical carcinoid; CI, confidence interval; LCNEC, large cell neuroendocrine carcinoma; SCLC, small cell carcinoma; SHR, subhazard ratio; STAS, spread through air spaces.